DK1178824T3 - Staphylococcus aureus-antigenholdig helcellevaccine - Google Patents

Staphylococcus aureus-antigenholdig helcellevaccine

Info

Publication number
DK1178824T3
DK1178824T3 DK00932194T DK00932194T DK1178824T3 DK 1178824 T3 DK1178824 T3 DK 1178824T3 DK 00932194 T DK00932194 T DK 00932194T DK 00932194 T DK00932194 T DK 00932194T DK 1178824 T3 DK1178824 T3 DK 1178824T3
Authority
DK
Denmark
Prior art keywords
antigen
aureus
type
whole cell
cell vaccine
Prior art date
Application number
DK00932194T
Other languages
English (en)
Inventor
Ali I Fattom
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of DK1178824T3 publication Critical patent/DK1178824T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
DK00932194T 1999-05-10 2000-05-10 Staphylococcus aureus-antigenholdig helcellevaccine DK1178824T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/307,775 US6294177B1 (en) 1996-09-11 1999-05-10 Staphylococcus aureus antigen-containing whole cell vaccine

Publications (1)

Publication Number Publication Date
DK1178824T3 true DK1178824T3 (da) 2006-10-09

Family

ID=23191126

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00932194T DK1178824T3 (da) 1999-05-10 2000-05-10 Staphylococcus aureus-antigenholdig helcellevaccine

Country Status (15)

Country Link
US (2) US6294177B1 (da)
EP (1) EP1178824B1 (da)
JP (1) JP2002544169A (da)
AT (1) ATE337015T1 (da)
AU (1) AU777218B2 (da)
BR (1) BR0010478A (da)
CA (1) CA2372633C (da)
CY (1) CY1105744T1 (da)
DE (1) DE60030274T2 (da)
DK (1) DK1178824T3 (da)
ES (1) ES2270835T3 (da)
MX (1) MXPA01011507A (da)
NZ (1) NZ515394A (da)
PT (1) PT1178824E (da)
WO (1) WO2000067785A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
EP2339344A1 (en) * 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
EP1576181B1 (en) * 2002-01-31 2013-08-14 Systagenix Wound Management IP Co. BV. Method for detecting pathogenic bacteria in wounds
DE60325945D1 (de) 2002-02-13 2009-03-12 Immunology Lab Inc Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
CN100351260C (zh) * 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
US20080095777A1 (en) 2004-09-22 2008-04-24 Glaxosmithkline Biologicals S.A. Immunogenic Composition for Use in Vaccination Against Staphylococcei
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
CN101795706B (zh) * 2007-05-28 2014-12-03 北里第一三共疫苗股份有限公司 副百日咳杆菌全菌体疫苗组合物
AU2007356845B2 (en) * 2007-07-23 2013-03-07 Vaccine Research International Plc Inactivated staphylococcal whole-cell vaccine
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (en) * 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
BRPI0916365A2 (pt) * 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc métodos e composições relacionados aos oligossacarídeos de glicosina beta-1,6 sintéticos
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections
US11896653B2 (en) 2017-09-13 2024-02-13 Unm Rainforest Innovations Silicified cell replicas, methods of making, and methods of using

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345864A1 (de) 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
IN164864B (da) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine

Also Published As

Publication number Publication date
AU777218B2 (en) 2004-10-07
JP2002544169A (ja) 2002-12-24
CA2372633A1 (en) 2000-11-16
PT1178824E (pt) 2007-01-31
DE60030274T2 (de) 2008-01-10
CY1105744T1 (el) 2010-12-22
ES2270835T3 (es) 2007-04-16
US6537559B2 (en) 2003-03-25
AU4995000A (en) 2000-11-21
US20020031528A1 (en) 2002-03-14
NZ515394A (en) 2004-11-26
MXPA01011507A (es) 2002-11-07
DE60030274D1 (de) 2006-10-05
EP1178824B1 (en) 2006-08-23
ATE337015T1 (de) 2006-09-15
BR0010478A (pt) 2002-05-21
US6294177B1 (en) 2001-09-25
CA2372633C (en) 2010-03-30
WO2000067785A2 (en) 2000-11-16
WO2000067785A3 (en) 2001-02-08
EP1178824A2 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
DK1178824T3 (da) Staphylococcus aureus-antigenholdig helcellevaccine
DK0925073T3 (da) Staphylococcus aureus antigen
DE60026691D1 (de) Staphylococcus-antigene und impstoff
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
CA2333732A1 (en) Redox reversible imidazole-osmium complex conjugates
BR0005106A (pt) Engate para acoplar um implemento a um veìculo utilitário
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
PT799058E (pt) Melhoramentos na funcao endometrica ou com ela relacionados
DE3853588T2 (de) Monoklonaler antikörper, spezifisch gegen den funktionellen adhäsionsbereich des oberflächenproteins einer phagocyten-zelle.
AU6303490A (en) Novel hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents
ATE69891T1 (de) Monoklonalantikoerperabfassung fuer diagnostischen gebrauch.
ES557292A0 (es) Procedimiento para la preparacion de un componente activo inmovilizado destinado al diagnostico.
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
FI881122A (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
CA2141025A1 (en) Anti-mucus glycoprotein monoclonal antibody
NO20022276L (no) Placental human neurokinin-B-forlöper
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
HUP0200345A2 (hu) Új nukleinsav-transzferáló ágensek, ezeket tartalmazó készítmények és alkalmazásuk
RU98123923A (ru) Штамм гибридных культивируемых клеток животных mus musculus l., используемый для получения моноклональных антител к chlamydia
UA43662A (uk) Спосіб оцінки пошкоджень моноцитів та альвеолярних макрофагів